Systematic review of the literature on clinical and experimental trials on the antitumor effects of cannabinoids in gliomas.

Posted on by

“To evaluate, through a systematic review of the literature, the antitumoral effects of cannabinoids on gliomas…

  In all experimental studies included, cannabinoids exerted antitumoral activity in vitro and/or antitumoral evidence in vivo in several models of tumor cells and tumors.

The antitumor activity included: antiproliferative effects (cell cycle arrest), decreased viability and cell death by toxicity, apoptosis, necrosis, autophagy, as well as antiangiogenic and antimigratory effects.

 Antitumoral evidence included: reduction in tumor size, antiangiogenic, and antimetastatic effects.

 Additionally, most of the studies described that the canabinnoids exercised selective antitumoral action in several distinct tumor models. Thereby, normal cells used as controls were not affected.

The safety factor in the cannabinoids’ administration has also been demonstrated in vivo.

 The various cannabinoids tested in multiple tumor models showed antitumoral effects both in vitro and in vivo.

 These findings indicate that cannabinoids are promising compounds for the treatment of gliomas.”

http://www.ncbi.nlm.nih.gov/pubmed/24142199

Cannabidiol, a non-psychoactive cannabinoid compound, affects metalloproteinases and pro-survival intracellular pathways in u87-mg human glioma cell line

Posted on by

“Malignant gliomas are the most common primary brain tumors… Recently, we have shown that the non-psychoactive cannabinoid compound cannabidiol (CBD) induced apoptosis of human glioma cells in vitro and tumor regression in vivo…the present study was to investigate the anti-migratory action of CBD…

 In conclusion, the present investigation adds further insights into the antitumoral action of the non-psychoactive CBD, showing multiple mechanisms through which the cannabinoid inhibits glioma cell growth and motility.

As CBD is a natural compound without psychotropic and side effects, these data lead us to consider CBD as a new potential anticancer drug useful in the management of gliomas.”

http://air.unimi.it/handle/2434/142533

Study: Marijuana’s Active Ingredient May Shrink Cancerous Tumors – FoxNews

Posted on by

“The active ingredient in marijuana appears to reduce tumor growth…

The researchers showed giving THC to mice with cancer decreased tumor growth and killed cells off in a process called autophagy.

“Our findings support that safe, therapeutically efficacious doses of THC may be reached in cancer patients,” Guillermo Velasco of Complutense University in Madrid and colleagues reported in the Journal of Clinical Investigation…

Other research has shown benefits, such as staving off Alzheimer’s, and many doctors view THC as a valuable way to treat weight loss associated with AIDS, and nausea and vomiting associated with chemotherapy in cancer patients.

Velasco and his team’s study included an analysis of two tumors from two people with a highly aggressive brain cancer which showed signs of autophagy after receiving THC.

The researchers said the findings could pave the way for cannabinoid-based drugs to treat cancer…”

More: http://www.foxnews.com/story/2009/04/02/study-marijuana-active-ingredient-may-shrink-cancerous-tumors/

“Cannabinoid action induces autophagy-mediated cell death through stimulation of ER stress in human glioma cells… These findings describe a mechanism by which THC can promote the autophagic death of human and mouse cancer cells and provide evidence that cannabinoid administration may be an effective therapeutic strategy for targeting human cancers.” http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2673842/

The endocannabinoid system and multiple sclerosis.

Posted on by

“Multiple sclerosis (MS) is a neurodegenerative disease that is characterised by repeated inflammatory/demyelinating events within the central nervous system (CNS). In addition to relapsing-remitting neurological insults, leading to loss of function, patients are often left with residual, troublesome symptoms such as spasticity and pain. These greatly diminish “quality of life” and have prompted some patients to self-medicate with and perceive benefit from cannabis.

Recent advances in cannabinoid biology are beginning to support these anecdotal observations, notably the demonstration that spasticity is tonically regulated by the endogenous cannabinoid system.

Recent clinical trials may indeed suggest that cannabis has some potential to relieve, pain, spasms and spasticity in MS. However, because the CB(1) cannabinoid receptor mediates both the positive and adverse effects of cannabis, therapy will invariably be associated with some unwanted, psychoactive effects.

In an experimental model of MS, and in MS tissue, there are local perturbations of the endocannabinoid system in lesional areas. Stimulation of endocannabinoid activity in these areas either through increase of synthesis or inhibition of endocannabinoid degradation offers the positive therapeutic potential of the cannabinoid system whilst limiting adverse events by locally targeting the lesion.

 In addition, CB(1) and CB(2) cannabinoid receptor stimulation may also have anti-inflammatory and neuroprotective potential as the endocannabinoid system controls the level of neurodegeneration that occurs as a result of the inflammatory insults.

Therefore cannabinoids may not only offer symptom control but may also slow the neurodegenerative disease progression that ultimately leads to the accumulation of disability.”

http://www.ncbi.nlm.nih.gov/pubmed/18781983

Cannabinoids ameliorate disease progression in a model of multiple sclerosis in mice, acting preferentially through CB1 receptor-mediated anti-inflammatory effects

Posted on by

“Cannabinoids have been proposed as promising therapeutic agents in MS given their capability to alleviate specific MS symptoms (e.g., spasticity, pain).

Although MS has been considered mainly an inflammatory disorder, recent evidence, however, revealed the importance of neurodegenerative events, opening the possibility that cannabinoid agonists, given their cytoprotective properties, may also serve to reduce oligodendrocyte death and axonal damage in MS.

Thus, the treatment with WIN55,512-2, a potent CB1 and CB2 agonist, was reported to be effective to ameliorate tremor and spasticity in mice with chronic relapsing experimental autoimmune encephalomyelitis, a murine model of MS, but also to delay disease progression in this and other murine models of MS….”

http://www.sciencedirect.com/science/article/pii/S0028390812000500

Control of Spasticity in a Multiple Sclerosis Model is mediated by CB1, not CB2, Cannabinoid Receptors

Posted on by

Figure 1

“There is increasing evidence to suggest that cannabis can ameliorate muscle-spasticity in multiple sclerosis, as was objectively shown in experimental autoimmune encephalomyelitis models. The purpose of this study was to investigate further the involvement of CB1 and CB2 cannabinoid receptors in the control of experimental spasticity…

Conclusions and Implications:

The CB1 receptor controls spasticity and cross-reactivity to this receptor appears to account for the therapeutic action of some CB2 agonists.

 As cannabinoid-induced psychoactivity is also mediated by the CB1 receptor, it will be difficult to truly dissociate the therapeutic effects from the well-known, adverse effects of cannabinoids when using cannabis as a medicine.

The lack of knowledge on the true diversity of the cannabinoid system coupled with the lack of total specificity of current cannabinoid reagents makes interpretation of in vivo results difficult, if using a purely pharmacological approach.

Gene knockout technology provides an important tool in target validation and indicates that the CB1 receptor is the main cannabinoid target for an anti-spastic effect.”

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2189718/

Control of spasticity in a multiple sclerosis model using central nervous system-excluded CB1 cannabinoid receptor agonists.

Posted on by

“The purpose of this study was the generation of central nervous system (CNS)-excluded cannabinoid receptor agonists to test the hypothesis that inhibition of spasticity, due to CNS autoimmunity, could be controlled by affecting neurotransmission within the periphery…

In summary, CNS-excluded CB1 receptor agonists are a novel class of therapeutic agent for spasticity.”

http://www.ncbi.nlm.nih.gov/pubmed/24121462

Chemicals in marijuana ‘protect nervous system’ against MS

Posted on by
Cannabis

“Chemical compounds found in marijuana can help treat multiple sclerosis-like diseases in mice by preventing inflammation in the brain and spinal cord, according to a study reported in the Journal of Neuroimmune Pharmacology.

“Inflammation is part of the body’s natural immune response, but in cases like MS, it gets out of hand,” says Dr. Ewa Kozela of Tel Aviv University, Israel.

“Our study looks at how compounds isolated from marijuana can be used to regulate inflammation to protect the nervous system and its functions.”

Dr. Kozela and colleagues set out to see if the known anti-inflammatory properties of two substances found in marijuana – the cannabinoids known as tetrahydrocannabinol (THC) and cannabidiol (CBD) – could also be applied to the treatment of inflammation associated with MS.

With either THC or CBD, the researchers treated immune cells that specifically target and harm the brain and spinal cord. In response to both chemicals, the immune cells, isolated from paralyzed mice, produced fewer inflammatory molecules, particularly interleukin 17 (IL-17).

Interleukin 17 “is strongly associated with MS and very harmful to nerve cells and their insulating covers,” the researchers say. They conclude:

“The presence of CBD or THC restrains the immune cells from triggering the production of inflammatory molecules, and limits the molecules’ ability to reach and damage the brain and spinal cord.” 

More: http://www.medicalnewstoday.com/articles/267161.php 

 

“Cannabinoids Decrease the Th17 Inflammatory Autoimmune Phenotype” http://link.springer.com/article/10.1007/s11481-013-9493-1

Chemicals in Marijuana Could Help Treat MS

Posted on by

TAU researchers have found that chemicals in marijuana could help treat multiple sclerosis. (Source: AFTAU)

“TAU researchers have found that chemicals in marijuana could help treat multiple sclerosis.

Multiple sclerosis is an inflammatory disease in which the immune system attacks the nervous system. The result can be a wide range of debilitating motor, physical, and mental problems. No one knows why people get the disease or how to treat it. 

In a new study published in the Journal of Neuroimmune Pharmacology, Drs. Ewa Kozela, Ana Juknat, Neta Rimmerman and Zvi Vogel of Tel Aviv University’s Dr. Miriam and Sheldon G. Adelson Center for the Biology of Addictive Diseases and Sackler Faculty of Medicine demonstrate that some chemical compounds found in marijuana can help treat MS-like diseases in mice by preventing inflammation in the brain and spinal cord…”
 
 

“Cannabinoids Decrease the Th17 Inflammatory Autoimmune Phenotype” http://link.springer.com/article/10.1007/s11481-013-9493-1 

Sending Multiple Sclerosis Up in Smoke

Posted on by

The illustration is of the cannabis sativa plant.

 “TAU researchers find chemicals in marijuana could help treat MS.

Multiple sclerosis is an inflammatory disease in which the immune system attacks the nervous system. The result can be a wide range of debilitating motor, physical, and mental problems. No one knows why people get the disease or how to treat it.

In a new study published in the Journal of Neuroimmune Pharmacology, Drs. Ewa Kozela, Ana Juknat, Neta Rimmerman and Zvi Vogel of Tel Aviv University’s Dr. Miriam and Sheldon G. Adelson Center for the Biology of Addictive Diseases and Sackler Faculty of Medicine demonstrate that some chemical compounds found in marijuana can help treat MS-like diseases in mice by preventing inflammation in the brain and spinal cord.

“Inflammation is part of the body’s natural immune response, but in cases like MS it gets out of hand,” says Kozela. “Our study looks at how compounds isolated from marijuana can be used to regulate inflammation to protect the nervous system and its functions.” Researchers from the Weizmann Institute of Science co-authored the study…”

More: http://neurosciencenews.com/neurology-thc-cbd-multiple-sclerosis-482/

 “Sending Multiple Sclerosis Up in Smoke” http://www.sciencedaily.com/releases/2013/10/131007132253.htm

“Cannabinoids Decrease the Th17 Inflammatory Autoimmune Phenotype” http://link.springer.com/article/10.1007/s11481-013-9493-1